Response to avelumab was comparable to non-binding durvalumab control conditions (Number 4F)
Response to avelumab was comparable to non-binding durvalumab control conditions (Number 4F). effectiveness, tolerability and accompanying biomarkers of ICIs in humans. Companion dogs suffering from neoplastic diseases possess gained attention as a highly relevant translational disease model. Despite successful reports of PD-1/PD-L1 blockade in pups, no compounds are available for veterinary medicine. Methods: Here, we…